A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors

Advanced Solid Tumor Clinical Trial

Official title:

A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study With Expansion Cohorts to Evaluate the Safety, Tolerability, and Preliminary Activity of LB101 in Subjects With Advanced Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05821777
• Other study ID #: LB101-101
• Secondary ID: 2022-003928-40
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: March 28, 2023
• Est. completion date: January 5, 2027

Study information

• Verified date: January 2024
• Source: Centessa Pharmaceuticals plc
• Contact: Centessa Pharmaceuticals
• Phone: 617-468-5770
• Email: lockbody101study[@]centessa.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess safety, tolerability, and preliminary activity of LB101 monotherapy in participants with advanced solid tumors.

Description:

This study consists of 2 parts: First in Human (FIH) dose escalation and dose optimization (Part 1a and Part 1b, respectively) and dose expansion (Part 2). Part 1 will evaluate LB101 monotherapy in participants with selected, advanced solid tumors and determine the Recommended Dose(s) for Expansion (RDE(s)) for Part 2. The design of Part 2 depends on the results of Part 1 and will further evaluate the safety, efficacy, tolerability, pharmacokinetics, and immune response of LB101.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 190
• Est. completion date: January 5, 2027
• Est. primary completion date: January 5, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female participants >= 18 years old
• Signed informed consent form (ICF)
• For Part 1: Participants who i). have a histologically confirmed solid tumor that is listed below and is advanced, unresectable, and/or metastatic and ii). have no standard therapy, are not candidates for available standard therapy, or have failed

systemic therapy due to lack of response, progression, or intolerance:

• Non-small cell lung cancer (NSCLC), which is known to be PD L1 positive (combined positive score [CPS] = 1 or tumor proportion score [TPS] = 1%) after having received pembrolizumab or other analog immune checkpoint inhibitor at any stage of their prior therapy I. Subjects with PD-L1 positive NSCLC with known genomic alterations for which targeted therapy is approved are not required to have been treated with pembrolizumab, etc. but must have received such approved targeted therapy. Genomic alternations include, but are not limited to, epidermal growth factor receptor [EGFR] and anaplastic lymphoma kinase [ALK]
• Head and neck squamous cell carcinoma or cervical cancer, which is known to be PD-L1-positive, after having received immune checkpoint inhibitor at any stage of their prior therapy
• Cutaneous squamous cell cancer after having received immune checkpoint inhibitor at any stage of their prior therapy
• Colorectal cancer with low level microsatellite instability (MSI-low) and/or microsatellite stable(MSS)
• Ovarian cancer which is platinum resistant or platinum refractory, with platinum free interval of less than 6 months, and without rapidly progressing disease in the investigator's judgment
• Gastric cancer which is known to be PD-L1 positive after having received pembrolizumab or other analog immune checkpoint inhibitor at any stage of their prior therapy
• Participants have measurable disease according to RECIST v1.1
• Available archived tumor tissue sample (Part 1a)
• In Part 1a backfill cohort(s), Part 1b, and Part 2, subjects must agree to undergo baseline tumor biopsy
• Participants have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Participants have adequate hematological function
• Participants have adequate hepatic and renal function
• Participants have a baseline QT interval as corrected by Fridericia's formula <= 480 milliseconds
• Participants with life expectancy >= 12 weeks
• Participants have a body weight >= 40 kilograms
• For female participants of childbearing potential:
• Negative urine or serum pregnancy test
• Willing to use 2 highly effective methods of contraception
• For male participants who can father a child:
• Willing to use 2 highly effective methods of contraception

Exclusion Criteria:

• Participants with unknown PD-L1 status for the following tumor types: NSCLC, head and neck squamous cell carcinoma, or cervical cancer a.In Part 1a backfill cohort(s), any subject with unknown PD-L1 status
• Participants with known negative PD-L1 status
• Participants with NSCLC, head and neck squamous cell carcinoma, cervical cancer, cutaneous squamous cell cancer, or gastric cancer that have NOT received checkpoint inhibitor for advanced/metastatic disease, unless such therapy is not approved for treating a subject's specific condition
• Participants who receive adjuvant systemic therapy and progressed with advanced disease within 6 months of completing treatment
• Participants who have had previous exposure to CD47 or SIRPa targeting anticancer therapy
• Participants participating in another interventional clinical study
• Participants who have ongoing side effects to any prior therapy or procedure, which have not recovered to NCI CTCAE Grade <= 1
• Participants who have received immunosuppressive drugs within 7 days prior to the start of LB101 or systemic glucocorticoids equivalent
• Participants who have received a live attenuated vaccine within 4 weeks prior to the start of LB101. For any subject receiving an approved severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, the investigator will be advised to follow the vaccine label and/or local guidance
• Participants with primary brain tumors and evidence of new or progressing cerebrospinal or leptomeningeal metastases
• Participants who have a history of Grade = 3 allergic reactions to monoclonal antibody therapy as well as known or suspected allergy or intolerance to any components of LB101
• Participants with active or suspected systemic inflammatory autoimmune diseases or with a history of documented autoimmune disease over the past 2 years
• Participants who have ongoing or active infection requiring IV anti-infective medications
• Participants with a known history of:
• Seropositivity for human immunodeficiency virus (HIV)
• Positive serology for hepatitis B, known history/positive serology for hepatitis C virus (HCV)
• Allogenic organ transplantation and/or hematopoietic stem cell transplantation
• Participants who have had a history of life-threatening treatment-related AEs with prior immunotherapy or who have not recovered from prior cancer therapy-induced AEs
• Participants with clinically significant ascites
• Participants with moderate bilateral pleural effusion or massive bilateral pleural effusion or respiratory dysfunction requiring drainage
• Participants with uncontrolled cardiovascular disease
• Participants with any other acute or chronic diseases, psychiatric disorders, or abnormal laboratory test values that, at the discretion of the investigators are deemed ineligible to participate
• Participants with a history of other advanced solid tumor malignancies except:
• Cured malignant tumors for > 2 years prior to enrollment and no known active disease
• Tumors with negligible risk of metastases or death
• Pregnant or lactating female participants

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Neoplasms

Intervention

Drug:
• LB101
Part 1: IV infusion of LB101 Q2W (28-day cycle) and Part 2: IV infusion of LB101

Locations

Country	Name	City	State
France	Institut Gustave Roussy	Villejuif
United States	Sarah Cannon Research Institute at HealthONE.	Denver	Colorado
United States	NEXT Oncology - Dallas	Irving	Texas
United States	Sarah Cannon Research Institute at Tennessee Oncology Nashville	Nashville	Tennessee
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	NEXT Oncology	San Antonio	Texas
United States	Sarah Cannon Research Institute at Florida Cancer Specialists	Sarasota	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Centessa Pharmaceuticals (UK) Limited	LockBody Therapeutics Ltd

Countries where clinical trial is conducted

United States,  France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 1: Number of Participants with Dose Limiting Toxicities (DLTs) as graded according to the NCI CTCAE v5.0		28 days following the first dose of LB101 (Days 1 to 28 of Cycle 1)
Primary	Part 1 and 2: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) as defined as events that started or worsened after first dose of study intervention until 30 days after last dose		From start of study treatment up to 3 years
Primary	Part 1: Number of Participants with Recommended Dose(s) for Expansion	Recommended Dose for expansion will be determined.	28 days following the first dose of LB101 (Days 1 to 28 of Cycle 1)
Primary	Part 2: Proportion of Participants with Confirmed Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Evaluated by the Blinded Independent Central Review (BICR)		Up to 3 years
Secondary	Part 1 and 2: Proportion of Participants with Objective Response Rate (ORR) According to RECIST v1.1 Evaluated by the Investigator		Up to 3 years
Secondary	Part 1 and 2: Duration of Response (DoR) According to RECIST v1.1 Evaluated by the Blinded Independent Central Review (BICR)		Time from first objective response to first occurrence of objective tumor progression or death from any cause (up to 3 years)
Secondary	Part 1 and 2: Proportion of Participants with Disease Control Rate (DCR) According to RECIST v1.1 Evaluated by the Blinded Independent Central Review (BICR)		Up to 3 years
Secondary	Part 1 and 2: Duration of Response (DoR) Assessed by Investigator		Time from first objective response to first occurrence of objective tumor progression or death from any cause (up to 3 years)
Secondary	Part 1 and 2: Disease Control Rate (DCR) Assessed by Investigator		Up to 3 years
Secondary	Part 1 and 2: Number of Participants with Antidrug Antibodies (ADA) and Neutralizing Antibodies (NAb) to LB101		Up to 3 years
Secondary	Part 1: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of LB101		Day 0 (pre-dose) and at multiple time points (up to End of infusion) post-dose in Cycle 1 (Day 1, 2, 3, 5, 8, 11, 15, 16, and 22), Cycle 2 (Day 1, 2, 8, and 15), Cycle 3 (Day 1, and 15), and Cycle 4 (Day 1, and 15)
Secondary	Part 2: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of LB101		Day 0 (pre-dose) and at multiple time points (up to End of infusion) post-dose in Cycle 1 (Day 1, 15, 16, and 22), Cycle 2 (Day 1, and 15), and Cycle 3 (Day 1, and 15)
Secondary	Part 1: Maximum (peak) Concentration (Cmax) of LB101		Day 0 (pre-dose) and at multiple time points (up to End of infusion) post-dose in Cycle 1 (Day 1, 2, 3, 5, 8, 11, 15, 16, and 22), Cycle 2 (Day 1, 2, 8, and 15), Cycle 3 (Day 1, and 15), and Cycle 4 (Day 1, and 15)
Secondary	Part 2: Maximum (peak) Concentration (Cmax) of LB101		Day 0 (pre-dose) and at multiple time points (up to End of infusion) post-dose in Cycle 1 (Day 1, 15, 16, and 22), Cycle 2 (Day 1, and 15), and Cycle 3 (Day 1, and 15)
Secondary	Part 1: Time to Maximum Observed Concentration (Tmax) of LB101		Day 0 (pre-dose) and at multiple time points (up to End of infusion) post-dose in Cycle 1 (Day 1, 2, 3, 5, 8, 11, 15, 16, and 22), Cycle 2 (Day 1, 2, 8, and 15), Cycle 3 (Day 1, and 15), and Cycle 4 (Day 1, and 15)
Secondary	Part 2: Time to Maximum Observed Concentration (Tmax) of LB101		Day 0 (pre-dose) and at multiple time points (up to End of infusion) post-dose in Cycle 1 (Day 1, 15, 16, and 22), Cycle 2 (Day 1, and 15), and Cycle 3 (Day 1, and 15)
Secondary	Part 1: Area Under the Concentration-time Curve at 14 days Post Drug Administration (AUC14days) of LB101		Day 0 (pre-dose) and at multiple time points (up to End of infusion) post-dose in Cycle 1 (Day 1, 2, 3, 5, 8, 11), Cycle 2 (Day 1, 2, and 8), Cycle 3 (Day 1), and Cycle 4 (Day 1)
Secondary	Part 2: Area Under the Concentration-time Curve at 14 days Post Drug Administration (AUC14days) of LB101		Day 0 (pre-dose) and at multiple time points (up to End of infusion) post-dose in Cycle 1 (Day 1), Cycle 2 (Day 1), and Cycle 3 (Day 1)
Secondary	Part 1: Area Under the Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-last) of LB101		Day 0 (pre-dose) and at multiple time points (up to End of infusion) post-dose in Cycle 1 (Day 1, 2, 3, 5, 8, 11, 15, 16, and 22), Cycle 2 (Day 1, 2, 8, and 15), Cycle 3 (Day 1, and 15), and Cycle 4 (Day 1, and 15)
Secondary	Part 2: Area Under the Concentration-time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-last) of LB101		Day 0 (pre-dose) and at multiple time points (up to End of infusion) post-dose in Cycle 1 (Day 1, 15, 16, and 22), Cycle 2 (Day 1, and 15), and Cycle 3 (Day 1, and 15)
Secondary	Part 1: Elimination Half-life (t1/2) of LB101		Day 0 (pre-dose) and at multiple time points (up to End of infusion) post-dose in Cycle 1 (Day 1, 2, 3, 5, 8, 11, 15, 16, and 22), Cycle 2 (Day 1, 2, 8, and 15), Cycle 3 (Day 1, and 15), and Cycle 4 (Day 1, and 15)
Secondary	Part 2: Elimination Half-life (t1/2) of LB101		Day 0 (pre-dose) and at multiple time points (up to End of infusion) post-dose in Cycle 1 (Day 1, 15, 16, and 22), Cycle 2 (Day 1, and 15), and Cycle 3 (Day 1, and 15)
Secondary	Part 1: Elimination Rate Constant (Kel) of LB101		Day 0 (pre-dose) and at multiple time points (up to End of infusion) post-dose in Cycle 1 (Day 1, 2, 3, 5, 8, 11, 15, 16, and 22), Cycle 2 (Day 1, 2, 8, and 15), Cycle 3 (Day 1, and 15), and Cycle 4 (Day 1, and 15)
Secondary	Part 2: Elimination Rate Constant (Kel) of LB101		Day 0 (pre-dose) and at multiple time points (up to End of infusion) post-dose in Cycle 1 (Day 1, 15, 16, and 22), Cycle 2 (Day 1, and 15), and Cycle 3 (Day 1, and 15)
Secondary	Part 1: Apparent Total Body Clearance (CL/F) of LB101		Day 0 (pre-dose) and at multiple time points (up to End of infusion) post-dose in Cycle 1 (Day 1, 2, 3, 5, 8, 11, 15, 16, and 22), Cycle 2 (Day 1, 2, 8, and 15), Cycle 3 (Day 1, and 15), and Cycle 4 (Day 1, and 15)
Secondary	Part 2: Apparent Total Body Clearance (CL/F) of LB101		Day 0 (pre-dose) and at multiple time points (up to End of infusion) post-dose in Cycle 1 (Day 1, 15, 16, and 22), Cycle 2 (Day 1, and 15), and Cycle 3 (Day 1, and 15)
Secondary	Part 1: Apparent Volume of Distribution (Vd/F) of LB101		Day 0 (pre-dose) and at multiple time points (up to End of infusion) post-dose in Cycle 1 (Day 1, 2, 3, 5, 8, 11, 15, 16, and 22), Cycle 2 (Day 1, 2, 8, and 15), Cycle 3 (Day 1, and 15), and Cycle 4 (Day 1, and 15)
Secondary	Part 2: Apparent Volume of Distribution (Vd/F) of LB101		Day 0 (pre-dose) and at multiple time points (up to End of infusion) post-dose in Cycle 1 (Day 1, 15, 16, and 22), Cycle 2 (Day 1, and 15), and Cycle 3 (Day 1, and 15)
Secondary	Part 1: Predose Trough Concentrations (CTrough) of LB101		Day 0 (pre-dose) and at multiple time points (up to End of infusion) post-dose in Cycle 1 (Day 1, 2, 3, 5, 8, 11, 15, 16, and 22), Cycle 2 (Day 1, 2, 8, and 15), Cycle 3 (Day 1, and 15), and Cycle 4 (Day 1, and 15)
Secondary	Part 2: Predose Trough Concentrations (CTrough) of LB101		Day 0 (pre-dose) and at multiple time points (up to End of infusion) post-dose in Cycle 1 (Day 1, 15, 16, and 22), Cycle 2 (Day 1, and 15), and Cycle 3 (Day 1, and 15)